SLC13A3抗体;SLC13A3 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human plasma, Human placenta tissue, Primary antibody: P12208(SLC13A3 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

The SLC13A3 antibody is a research tool targeting the solute carrier family 13 member 3 (SLC13A3) protein, a sodium-dependent dicarboxylate transporter. SLC13A3 facilitates cellular uptake of dicarboxylates like succinate, citrate, and α-ketoglutarate, which are critical intermediates in metabolic pathways such as the tricarboxylic acid (TCA) cycle. Primarily expressed in the kidney, liver, and placenta, SLC13A3 regulates energy homeostasis, pH balance, and renal reabsorption processes. Its role extends to mitochondrial function, gluconeogenesis, and lipid synthesis.

Antibodies against SLC13A3 are used to study its expression, localization, and function in physiological and pathological contexts. Research links SLC13A3 dysregulation to diseases including renal disorders, metabolic syndromes, and cancers. For instance, reduced SLC13A3 expression has been observed in renal cell carcinoma, while overexpression may influence cancer cell metabolism. The antibody aids in detecting protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence, providing insights into tissue-specific distribution and disease mechanisms.

Commercial SLC13A3 antibodies are typically developed in rabbits or mice, validated for specificity across human, mouse, or rat samples. Understanding SLC13A3's role through antibody-based studies could uncover therapeutic targets for metabolic diseases or cancer, highlighting its potential in translational research.